Close
Achema middle east
swop processing & packaging

Wockhardt-Serum Institute of India Bond For Vaccines In UK

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Matica Bio Gets a U.S. Biotech Commercial Manufacturing Deal

Matica Biotechnology, Inc., which happens to be a leading...

The Latest Breakthroughs in Dental Treatments

Dental care has moved well beyond fillings and routine...

How Can Digital Tools Improve Medication Adherence in Patients?

Medication adherence has long been one of healthcare’s toughest...

Russia, Vietnam Collaborate on Biopharma Technology Transfer

Russia and Vietnam have gone on to officially formalize...

Wockhardt, located in India, and a Serum Institute of India affiliate have agreed to develop a new fill-finish production facility in Wrexham, North Wales (PDF). Financial information, as well as data on the initiation of the project, the size of the facility, and the expected number of jobs created by the project, were not made public. Wockhardt predicts that the facility will produce 150 million doses of different vaccinations each year.

Wockhardt has positioned itself as one of the country’s largest drug suppliers, supplying medications to the National Health Service out of its present 612,000-square-foot production facility in Wrexham, which employs over 400 people. Diabetes, anticoagulation, pain management, and COVID-19 vaccines have all been manufactured at the location. In a statement, Natasha Poonawalla, chairman of Serum Life Sciences, stated that the partnership will be crucial in developing long-term capability in the U.K. as they seek to further improve supply resilience and assist in the global deployment of vaccines.

After reaching a contract with the British government in the summer of 2020 to execute fill-finish work on thousands of COVID-19 vaccine doses for exclusive use in the United Kingdom, including AstraZeneca and the University of Oxford’s shot, Wockhardt began ramping up its Wrexham plant. The UK government paid 65.5 million pounds for the Wockhardt COVID-19 agreement at the time before agreeing to further advance purchases from Pfizer, BioNTech, and other companies.

Latest stories

Related stories

Matica Bio Gets a U.S. Biotech Commercial Manufacturing Deal

Matica Biotechnology, Inc., which happens to be a leading...

The Latest Breakthroughs in Dental Treatments

Dental care has moved well beyond fillings and routine...

How Can Digital Tools Improve Medication Adherence in Patients?

Medication adherence has long been one of healthcare’s toughest...

Russia, Vietnam Collaborate on Biopharma Technology Transfer

Russia and Vietnam have gone on to officially formalize...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »